{"id":2368,"date":"2018-08-30T15:57:00","date_gmt":"2018-08-30T15:57:00","guid":{"rendered":"http:\/\/staging.grindeks.eu\/turnover-of-grindeks-reaches-71-5-million-euro-in-the-first-six-months-of-2018-profit-6-7-million-euro\/"},"modified":"2022-07-04T15:59:46","modified_gmt":"2022-07-04T15:59:46","slug":"turnover-of-grindeks-reaches-71-5-million-euro-in-the-first-six-months-of-2018-profit-6-7-million-euro","status":"publish","type":"post","link":"https:\/\/grindeks.com\/lv\/turnover-of-grindeks-reaches-71-5-million-euro-in-the-first-six-months-of-2018-profit-6-7-million-euro\/","title":{"rendered":"2018. gada pirmaj\u0101 pusgad\u0101 Grindeks sasniedz 71,5 milj. eiro apgroz\u012bjumu un 6,7 milj. eiro pe\u013c\u0146u"},"content":{"rendered":"\n<p>\u0160odien, 30. august\u0101, akciju sabiedr\u012bbas Grindeks \u201eNasdaq Riga\u201d iesniegtie 2018. gada pirm\u0101 pusgada nerevid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati liecina, ka Koncerna apgroz\u012bjums 2018. gada pirmaj\u0101 pusgad\u0101 bija 71,5 milj. eiro, kas ir par 3,3 milj. eiro vai par 5% vair\u0101k nek\u0101 2017. gada pirmaj\u0101 pusgad\u0101. Savuk\u0101rt koncerna neto pe\u013c\u0146a, kas attiecin\u0101ma uz m\u0101tes sabiedr\u012bbas akcion\u0101riem, 2018. gada pirmaj\u0101 pusgad\u0101 bija 6,7 milj. eiro, kas, sal\u012bdzinot ar 2017. gada pirmo pusgadu, ir palielin\u0101jusies par 0,25 milj. eiro vai par 4%.<\/p>\n\n\n\n<p>Bruto pe\u013c\u0146as rentabilit\u0101te 2018. gada pirmaj\u0101 pusgad\u0101 bija 58%, savuk\u0101rt t\u012br\u0101s pe\u013c\u0146as rentabilit\u0101te bija 9%. 2018. gada pirmaj\u0101 pusgad\u0101 Koncerna sara\u017eot\u0101 produkcija eksport\u0113ta uz 75 pasaules valst\u012bm kopum\u0101 par 65,7 milj. eiro, kas ir par 4,5 milj. eiro vai par 7% vair\u0101k nek\u0101 2017. gada pirmaj\u0101 pusgad\u0101.<\/p>\n\n\n\n<p>AS Grindeks padomes priek\u0161s\u0113d\u0113t\u0101js Kirovs Lipmans: \u201ePateicoties ilgtsp\u0113j\u012bgam redz\u0113jumam, Grindeks sp\u0113j p\u0101rdom\u0101ti piel\u0101goties glob\u0101laj\u0101m farm\u0101cijas tirgus pras\u012bb\u0101m un konkurencei. Inov\u0101cijas un past\u0101v\u012bga produktu portfe\u013ca att\u012bst\u012bba, k\u0101 ar\u012b nep\u0101rtraukti ieguld\u012bjumi m\u0101rketing\u0101 un p\u0101rdo\u0161an\u0101 sekm\u0113 Grindeks padomes izvirz\u012bto m\u0113r\u0137u sasnieg\u0161anu.\u201d<\/p>\n\n\n\n<p>Grindeks gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms 2018. gada pirmaj\u0101 pusgad\u0101 bija 65,6 milj. eiro un ir palielin\u0101jies, sal\u012bdzinot 2017. gada pirmo pusgadu, par 3,9 milj. eiro vai 6%. P\u0101rdo\u0161anas apjoms Krievij\u0101, p\u0101r\u0113j\u0101s NVS valst\u012bs un Gruzij\u0101 2018. gada pirmaj\u0101 pusgad\u0101 sasniedza 43,1 milj. eiro, kas ir par 1,4 milj. eiro vai par 3% vair\u0101k nek\u0101 2017. gada pirmaj\u0101 pusgad\u0101. Sal\u012bdzinot ar 2017. gada pirmo pusgadu, 2018. gada pirmaj\u0101 pusgad\u0101, iev\u0113rojam\u0101kais p\u0101rdo\u0161anas apjoma pieaugums sasniegts \u2013 Uzbekist\u0101n\u0101 par 35%, Kirgizst\u0101n\u0101 par 28%, Kazahst\u0101n\u0101 par 21%, Arm\u0113nij\u0101 un Baltkrievij\u0101 par 15%, Ukrain\u0101 par 12%.<\/p>\n\n\n\n<p>Gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms Eiropas Savien\u012bbas valst\u012bs 2018. gada pirmaj\u0101 pusgad\u0101 sasniedza 21,3 milj. eiro, kas ir par 2,5 milj. eiro vai 13% vair\u0101k nek\u0101 2017. gada pirmaj\u0101 pusgad\u0101. P\u0101rdo\u0161anas apjoms 2018. gada pirmaj\u0101 pusgad\u0101, sal\u012bdzinot ar 2017. gada pirmo pusgadu, Polij\u0101 ir palielin\u0101jies 4 reizes, \u010cehij\u0101 2,3 reizes, Somij\u0101 par 89%, D\u0101nij\u0101 par 68%, N\u012bderland\u0113 par 64% un Slov\u0101kij\u0101 par 34%.<\/p>\n\n\n\n<p>2018. gada pirmaj\u0101 pusgad\u0101 akt\u012bvo farmaceitisko vielu p\u0101rdo\u0161anas apjoms sasniedza 4,3 milj. eiro, kas ir par 0,52 milj. eiro vai 14% vair\u0101k nek\u0101 2017. gada pirmaj\u0101 pusgad\u0101. \u0160aj\u0101 period\u0101 liel\u0101kais Grindeks akt\u012bvo farmaceitisko vielu eksports tikai veikts uz ES valst\u012bm, Jap\u0101nu, Austr\u0101liju un ASV. Grindeks piepras\u012bt\u0101k\u0101s akt\u012bv\u0101s farmaceitisk\u0101s vielas 2018. gada pirmaj\u0101 pusgad\u0101 bija deksmedetomid\u012bns, zopiklons, pimobend\u0101ns, ftoraf\u016brs, oksitoc\u012bns, medetomid\u012bns, detomid\u012bns, atipamezols.<\/p>\n\n\n\n<p>AS Grindeks valdes priek\u0161s\u0113d\u0113t\u0101js Juris Bundulis: \u201e\u0122eogr\u0101fiski analiz\u0113jot 2018. gada pirm\u0101 pusgada rezult\u0101tus, liel\u0101kais p\u0101rdo\u0161anas apjomu k\u0101pums sasniegts Eiropas Savien\u012bbas valst\u012bs, kas atbilst m\u016bsu ilgtermi\u0146a strat\u0113\u0123ijai palielin\u0101t Grindeks kl\u0101tb\u016btni stabil\u0101 un prognoz\u0113jam\u0101 Eiropas farm\u0101cijas tirg\u016b. Glob\u0101l\u0101 konkurence saglab\u0101jas spraiga, un Grindeks izmantos visas priek\u0161roc\u012bbas, lai savus m\u0113r\u0137us sasniegtu.\u201d<\/p>\n\n\n\n<p>Finan\u0161u p\u0101rskatus skat\u012bt:&nbsp;<a href=\"https:\/\/grindeks.lv\/lv\/investoriem\/finansu-atskaites\/\" target=\"_blank\" rel=\"noopener\">https:\/\/grindeks.lv\/lv\/investoriem\/finansu-atskaites\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u0160odien, 30. august\u0101, akciju sabiedr\u012bbas Grindeks \u201eNasdaq Riga\u201d iesniegtie 2018. gada pirm\u0101 pusgada nerevid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati liecina, ka Koncerna apgroz\u012bjums 2018. gada pirmaj\u0101 pusgad\u0101&#8230;<\/p>\n","protected":false},"author":3,"featured_media":2365,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-2368","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/2368","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=2368"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/2368\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/2365"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=2368"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=2368"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=2368"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}